Through continuous and dynamic postoperative monitoring of the changes in the cancer genome panorama in the free DNA of the peripheral blood, in combination with specific tumor markers, big data and artificial intelligence, calculate the patient's cancer recurrence index (CRI) to achieve personalized monitoring and risk assessment of recurrence.
▪ Adopt a new multivariate algorithm combined with artificial intelligence to assess the risk of postoperative recurrence of cancer patients at the molecular level
Copyright©2021
Shenzhen yucebio Technology Co., Ltd. all rights reserved
Yueicp no.16128839
